Clinical trial · Interventional
Fertility Sparing Therapy for Patients With Stage IA G2 Endometrial Cancer
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Endometrial cancer (EC) is a prevalent gynecological cancer with an escalating global incidence and a decreasing age of onset. In the era of precision medicine, there is an increasing emphasis on tailoring treatments to different populations to optimize the positive impact of clinical interventions. Fertility-sparing therapies (FST) are gaining popularity for early-stage, low-grade endometrial cancer due to mounting evidence supporting favorable oncologic and pregnancy outcomes. However, consensus regarding the feasibility of fertility-sparing therapy for similar low-risk grade-2 (G2) endometrioid adenocarcinoma remains elusive. Given the uncertainties surrounding fertility-preserving therapy in patients with moderately differentiated endometrial cancer, this study aims to investigate the optimal regimen of fertility-preserving therapy for patients with IAG2.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Carcinoma, Endometrioid | Endometrioid Adenocarcinoma | ALIAS | 0.90 |
| Fertility Preservation | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d. | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Study on Fertility Sparing Therapy in IA Stage G2 Endometrial Cancer Patients
- description
- Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
- interventionNames
- Drug: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
- type
- EXPERIMENTAL
- label
- The Study on Fertility Sparing Therapy in IA Stage G2 Endometrial Cancer Patients
- description
- Treatment Option 2 is a combination therapy, consisting of oral MPA 500mg/d/MA 320mg/d combined with the intrauterine insertion of the levonorgestrel intrauterine system (LNG-IUS, Mirena IUD).
- interventionNames
- Drug: Treatment Option 1 is a single-drug regimen, with oral medroxyprogesterone acetate (MPA) 500mg/d or MA 320mg/d.
Primary outcomes (1)
Eligibility
Eligibility (as posted)
- Sex
- Female
- Maximum age
- 45 Years
Show eligibility criteria text
Inclusion Criteria: * Endometrioid adenocarcinoma G2, diagnosis by pathological. * The lesion is limited to the endometrium. * FIGO (2009) staging is IA. * Age less than 45. * Strongly request to preserve fertility. * Sign informed consent. Exclusion Criteria: * The tumor has invaded the muscle layer. * FIGO (2009) stage IB or higher. * Endometrioid adenocarcinoma G1, G3, or non-endometrioid cancer * There are malignant tumors in other systems. * Have contraindications for conservative treatment or drug use. * Have been judged by the researcher to be unsuitable for childbearing.
References
Publications (0)
Data not yet available